Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5960
    +0.0023 (+0.39%)
     

  • NZD/EUR

    0.5555
    +0.0009 (+0.16%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.87
    +0.06 (+0.07%)
     

  • GOLD

    2,337.70
    -0.70 (-0.03%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,093.65
    +53.27 (+0.66%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,979.37
    -109.33 (-0.60%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • NZD/JPY

    92.7040
    +0.5890 (+0.64%)
     

G1 Therapeutics, Inc. (GTHX) Q2 2022 Earnings Call Transcript

Motley Fool Transcribing, The Motley Fool
·34-min read
G1 Therapeutics, Inc. (GTHX) Q2 2022 Earnings Call Transcript

Good morning, everyone, and welcome to the G1 conference call to discuss our second quarter '22 financial results and business update. The press release on these financial results was issued this morning and can be found in the news section of our corporate website, g1therapeutics.com. On this morning's call, the team will provide a business overview of the second quarter of '22, including an update on our clinical programs and our commercial progress in that period with Cosela, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum etoposide containing regimen or topotecan containing regimen for extensive-stage small cell lung cancer or ES-SCLC.

Continue reading